Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim has over 100 years of heritage in respiratory disease. 

Since 1921 we have emerged as a leader in this disease area, having developed and launched treatments for a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer.

Our focus is on improving the life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.

Contact Boehringer Ingelheim:

Boehringer Ingelheim Ireland Ltd , 4045 Kingswood Road, Citywest Business Campus, Co. Dublin, D24 VO6K.  tel: +353 (0)1 2959620

Boehringer Ingelheim Ltd has sponsored this meeting by means of financial support to display a web-based exhibition page, BI has had no input into the agenda.

Ofev (nintedanib) is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). 

Ofev is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.1

IPF is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause. It is characterised by worsening breathlessness and irreversible loss of lung function. 2-4 

Despite being a rare disease, IPF accounts for around 1% of all UK deaths and almost 5% of all lung-related deaths, according to 2012 data.5 

Mortality can be precipitated by acute exacerbations of IPF, which may occur at any time; around 50% of patients hospitalised for an acute exacerbation die in hospital.3,6

IPF Does not wait. Act Fast!2

If you would like more information from our local representative, please use the following contact details:

Alan O’Connell Key Account Specialist – IPF, 

+353 (87) 2636753

 Adverse events should be reported to the Health Products Regulatory Authority at or by email to . Adverse events should also be reported to Boehringer Ingelheim Pharmacovigilance on 01 291 3960 or by email to

PC-IE-101665     November 2022


  1. OFEV® 100 mg and 150 mg soft capsules Summary of Product Characteristics. Boehringer Ingelheim.
  2. Raghu G et al. Am J Respir Crit Care Med 2011;183:788–824.
  3. Kim KJ et al. Respir Med 2015;109:661–670.
  4. Molina-Molina M et al. Expert Rev Respir Med 2018;12:537–539.
  5. British Lung Foundation. Available at (accessed May 2020).
  6. Ryerson CJ et al. Eur Respir J 2015;46:512–520